nodes	percent_of_prediction	percent_of_DWPC	metapath
Mesoridazine—CYP2D6—breast cancer	0.352	1	CbGaD
Mesoridazine—HTR6—Raloxifene—breast cancer	0.214	0.613	CbGbCtD
Mesoridazine—Promazine—Tamoxifen—breast cancer	0.146	1	CrCrCtD
Mesoridazine—CYP2D6—Idarubicin—breast cancer	0.056	0.16	CbGbCtD
Mesoridazine—CYP2D6—Vinorelbine—breast cancer	0.0273	0.0782	CbGbCtD
Mesoridazine—CYP2D6—Tamoxifen—breast cancer	0.0247	0.0706	CbGbCtD
Mesoridazine—CYP2D6—Vinblastine—breast cancer	0.0169	0.0482	CbGbCtD
Mesoridazine—CYP2D6—Doxorubicin—breast cancer	0.0104	0.0296	CbGbCtD
Mesoridazine—Trifluoperazine—S100A4—breast cancer	0.00163	0.209	CrCbGaD
Mesoridazine—Encainide—CYP2D6—breast cancer	0.000464	0.0595	CrCbGaD
Mesoridazine—Ethopropazine—BCHE—breast cancer	0.000393	0.0504	CrCbGaD
Mesoridazine—Clemastine—CYP2D6—breast cancer	0.000345	0.0442	CrCbGaD
Mesoridazine—Eletriptan—PTGS1—breast cancer	0.000342	0.0439	CrCbGaD
Mesoridazine—Triflupromazine—BCHE—breast cancer	0.000322	0.0412	CrCbGaD
Mesoridazine—Clemastine—CYP3A4—breast cancer	0.000296	0.0379	CrCbGaD
Mesoridazine—Eletriptan—CYP2D6—breast cancer	0.000233	0.0299	CrCbGaD
Mesoridazine—Mequitazine—CYP2D6—breast cancer	0.000221	0.0283	CrCbGaD
Mesoridazine—Alimemazine—CYP3A4—breast cancer	0.00022	0.0282	CrCbGaD
Mesoridazine—Eletriptan—CYP3A4—breast cancer	0.0002	0.0256	CrCbGaD
Mesoridazine—Mequitazine—CYP3A4—breast cancer	0.000189	0.0243	CrCbGaD
Mesoridazine—Eletriptan—ABCB1—breast cancer	0.000166	0.0213	CrCbGaD
Mesoridazine—Pipotiazine—CYP2D6—breast cancer	0.000157	0.0201	CrCbGaD
Mesoridazine—Thiothixene—CYP2D6—breast cancer	0.000157	0.0201	CrCbGaD
Mesoridazine—Chlorpromazine—BCHE—breast cancer	0.000155	0.0199	CrCbGaD
Mesoridazine—Prochlorperazine—CYP2D6—breast cancer	0.00015	0.0192	CrCbGaD
Mesoridazine—Fluphenazine—CYP2D6—breast cancer	0.000136	0.0174	CrCbGaD
Mesoridazine—Pipotiazine—CYP3A4—breast cancer	0.000135	0.0173	CrCbGaD
Mesoridazine—Prochlorperazine—CYP3A4—breast cancer	0.000129	0.0165	CrCbGaD
Mesoridazine—Triflupromazine—ABCB1—breast cancer	0.000126	0.0162	CrCbGaD
Mesoridazine—Acepromazine—ALB—breast cancer	0.000122	0.0157	CrCbGaD
Mesoridazine—Thioproperazine—ALB—breast cancer	0.000119	0.0153	CrCbGaD
Mesoridazine—Thiothixene—ALB—breast cancer	0.000117	0.0151	CrCbGaD
Mesoridazine—Pipotiazine—ALB—breast cancer	0.000117	0.0151	CrCbGaD
Mesoridazine—Thioridazine—CYP2D6—breast cancer	0.000117	0.015	CrCbGaD
Mesoridazine—Methotrimeprazine—CYP2D6—breast cancer	0.000112	0.0143	CrCbGaD
Mesoridazine—Promethazine—CYP2D6—breast cancer	0.00011	0.0141	CrCbGaD
Mesoridazine—Perphenazine—CYP2D6—breast cancer	0.000107	0.0138	CrCbGaD
Mesoridazine—Fluphenazine—ABCB1—breast cancer	9.69e-05	0.0124	CrCbGaD
Mesoridazine—Perphenazine—CYP3A4—breast cancer	9.2e-05	0.0118	CrCbGaD
Mesoridazine—Chlorpromazine—CYP2D6—breast cancer	8.51e-05	0.0109	CrCbGaD
Mesoridazine—Promazine—CYP3A4—breast cancer	8.3e-05	0.0106	CrCbGaD
Mesoridazine—Promethazine—ABCB1—breast cancer	7.85e-05	0.0101	CrCbGaD
Mesoridazine—Trifluoperazine—ABCB1—breast cancer	7.75e-05	0.00993	CrCbGaD
Mesoridazine—Chlorpromazine—CYP3A4—breast cancer	7.3e-05	0.00936	CrCbGaD
Mesoridazine—Chlorpromazine—ALB—breast cancer	6.37e-05	0.00817	CrCbGaD
Mesoridazine—Chlorpromazine—ABCB1—breast cancer	6.08e-05	0.00779	CrCbGaD
Mesoridazine—DRD3—Signaling Pathways—CDKN1A—breast cancer	7.33e-06	5.05e-05	CbGpPWpGaD
Mesoridazine—DRD3—Signaling Pathways—PTEN—breast cancer	7.32e-06	5.04e-05	CbGpPWpGaD
Mesoridazine—HTR2A—Signaling Pathways—PIK3CD—breast cancer	7.32e-06	5.04e-05	CbGpPWpGaD
Mesoridazine—HRH1—Signaling Pathways—PIK3CD—breast cancer	7.3e-06	5.03e-05	CbGpPWpGaD
Mesoridazine—DRD2—Signaling by GPCR—KRAS—breast cancer	7.28e-06	5.02e-05	CbGpPWpGaD
Mesoridazine—HTR2A—GPCR downstream signaling—PIK3CA—breast cancer	7.25e-06	4.99e-05	CbGpPWpGaD
Mesoridazine—HTR2A—Signaling Pathways—SERPINE1—breast cancer	7.24e-06	4.99e-05	CbGpPWpGaD
Mesoridazine—HRH1—GPCR downstream signaling—PIK3CA—breast cancer	7.23e-06	4.98e-05	CbGpPWpGaD
Mesoridazine—HRH1—Signaling Pathways—SERPINE1—breast cancer	7.22e-06	4.97e-05	CbGpPWpGaD
Mesoridazine—CHRM2—Signaling Pathways—PIK3CD—breast cancer	7.18e-06	4.95e-05	CbGpPWpGaD
Mesoridazine—HTR2A—Signaling by GPCR—KRAS—breast cancer	7.16e-06	4.93e-05	CbGpPWpGaD
Mesoridazine—HTR6—Signaling Pathways—MYC—breast cancer	7.16e-06	4.93e-05	CbGpPWpGaD
Mesoridazine—DRD3—Signaling Pathways—MAPK8—breast cancer	7.16e-06	4.93e-05	CbGpPWpGaD
Mesoridazine—HRH1—Signaling by GPCR—KRAS—breast cancer	7.15e-06	4.92e-05	CbGpPWpGaD
Mesoridazine—HTR6—Signaling Pathways—TGFB1—breast cancer	7.14e-06	4.92e-05	CbGpPWpGaD
Mesoridazine—DRD3—Signaling by GPCR—AKT1—breast cancer	7.14e-06	4.92e-05	CbGpPWpGaD
Mesoridazine—CHRM2—GPCR downstream signaling—PIK3CA—breast cancer	7.11e-06	4.9e-05	CbGpPWpGaD
Mesoridazine—CHRM2—Signaling Pathways—SERPINE1—breast cancer	7.1e-06	4.89e-05	CbGpPWpGaD
Mesoridazine—HTR1A—Signaling Pathways—CXCL8—breast cancer	7.09e-06	4.89e-05	CbGpPWpGaD
Mesoridazine—HTR2C—Signaling Pathways—CXCL8—breast cancer	7.06e-06	4.86e-05	CbGpPWpGaD
Mesoridazine—HTR1A—Signaling by GPCR—HRAS—breast cancer	7.05e-06	4.86e-05	CbGpPWpGaD
Mesoridazine—CHRM2—Signaling by GPCR—KRAS—breast cancer	7.03e-06	4.85e-05	CbGpPWpGaD
Mesoridazine—CYP2D6—Metabolism—MTHFR—breast cancer	7.02e-06	4.84e-05	CbGpPWpGaD
Mesoridazine—DRD2—Signaling Pathways—NOS3—breast cancer	7.02e-06	4.84e-05	CbGpPWpGaD
Mesoridazine—HTR2C—Signaling by GPCR—HRAS—breast cancer	7.01e-06	4.83e-05	CbGpPWpGaD
Mesoridazine—HTR6—Signaling Pathways—EGFR—breast cancer	7e-06	4.83e-05	CbGpPWpGaD
Mesoridazine—HTR1A—Signaling Pathways—CDKN1B—breast cancer	6.93e-06	4.77e-05	CbGpPWpGaD
Mesoridazine—HTR2A—Signaling Pathways—NOS3—breast cancer	6.91e-06	4.76e-05	CbGpPWpGaD
Mesoridazine—HRH1—Signaling Pathways—NOS3—breast cancer	6.89e-06	4.75e-05	CbGpPWpGaD
Mesoridazine—HTR2C—Signaling Pathways—CDKN1B—breast cancer	6.89e-06	4.75e-05	CbGpPWpGaD
Mesoridazine—HTR1A—GPCR downstream signaling—AKT1—breast cancer	6.85e-06	4.72e-05	CbGpPWpGaD
Mesoridazine—HTR2C—GPCR downstream signaling—AKT1—breast cancer	6.82e-06	4.7e-05	CbGpPWpGaD
Mesoridazine—HTR1A—Signaling Pathways—CASP3—breast cancer	6.79e-06	4.68e-05	CbGpPWpGaD
Mesoridazine—DRD3—Signaling Pathways—SRC—breast cancer	6.79e-06	4.68e-05	CbGpPWpGaD
Mesoridazine—CHRM2—Signaling Pathways—NOS3—breast cancer	6.78e-06	4.67e-05	CbGpPWpGaD
Mesoridazine—HTR1A—Signaling Pathways—IL2—breast cancer	6.78e-06	4.67e-05	CbGpPWpGaD
Mesoridazine—HTR2C—Signaling Pathways—CASP3—breast cancer	6.75e-06	4.65e-05	CbGpPWpGaD
Mesoridazine—HTR1A—Signaling by GPCR—IL6—breast cancer	6.74e-06	4.65e-05	CbGpPWpGaD
Mesoridazine—HTR2C—Signaling Pathways—IL2—breast cancer	6.74e-06	4.65e-05	CbGpPWpGaD
Mesoridazine—HTR2C—Signaling by GPCR—IL6—breast cancer	6.71e-06	4.62e-05	CbGpPWpGaD
Mesoridazine—DRD2—Signaling by GPCR—PIK3CA—breast cancer	6.69e-06	4.61e-05	CbGpPWpGaD
Mesoridazine—DRD2—Signaling Pathways—MDM2—breast cancer	6.66e-06	4.59e-05	CbGpPWpGaD
Mesoridazine—DRD2—Signaling Pathways—RAF1—breast cancer	6.64e-06	4.57e-05	CbGpPWpGaD
Mesoridazine—HTR6—Signaling Pathways—KRAS—breast cancer	6.62e-06	4.56e-05	CbGpPWpGaD
Mesoridazine—DRD3—Signaling Pathways—VEGFA—breast cancer	6.61e-06	4.55e-05	CbGpPWpGaD
Mesoridazine—DRD2—Signaling Pathways—RELA—breast cancer	6.61e-06	4.55e-05	CbGpPWpGaD
Mesoridazine—HTR1A—Signaling Pathways—CCND1—breast cancer	6.61e-06	4.55e-05	CbGpPWpGaD
Mesoridazine—HTR1A—Signaling Pathways—JUN—breast cancer	6.59e-06	4.54e-05	CbGpPWpGaD
Mesoridazine—HTR2A—Signaling by GPCR—PIK3CA—breast cancer	6.58e-06	4.53e-05	CbGpPWpGaD
Mesoridazine—HTR2C—Signaling Pathways—CCND1—breast cancer	6.57e-06	4.53e-05	CbGpPWpGaD
Mesoridazine—DRD2—Signaling Pathways—ERBB2—breast cancer	6.57e-06	4.52e-05	CbGpPWpGaD
Mesoridazine—HRH1—Signaling by GPCR—PIK3CA—breast cancer	6.57e-06	4.52e-05	CbGpPWpGaD
Mesoridazine—HTR2C—Signaling Pathways—JUN—breast cancer	6.56e-06	4.52e-05	CbGpPWpGaD
Mesoridazine—HTR2A—Signaling Pathways—MDM2—breast cancer	6.55e-06	4.52e-05	CbGpPWpGaD
Mesoridazine—DRD3—Signaling Pathways—STAT3—breast cancer	6.55e-06	4.51e-05	CbGpPWpGaD
Mesoridazine—HTR1A—Signaling Pathways—CTNNB1—breast cancer	6.54e-06	4.51e-05	CbGpPWpGaD
Mesoridazine—HRH1—Signaling Pathways—MDM2—breast cancer	6.54e-06	4.51e-05	CbGpPWpGaD
Mesoridazine—HTR2A—Signaling Pathways—RAF1—breast cancer	6.53e-06	4.5e-05	CbGpPWpGaD
Mesoridazine—HRH1—Signaling Pathways—RAF1—breast cancer	6.52e-06	4.49e-05	CbGpPWpGaD
Mesoridazine—HTR2C—Signaling Pathways—CTNNB1—breast cancer	6.51e-06	4.49e-05	CbGpPWpGaD
Mesoridazine—HTR2A—Signaling Pathways—RELA—breast cancer	6.5e-06	4.48e-05	CbGpPWpGaD
Mesoridazine—HRH1—Signaling Pathways—RELA—breast cancer	6.49e-06	4.47e-05	CbGpPWpGaD
Mesoridazine—DRD2—Signaling Pathways—MTOR—breast cancer	6.48e-06	4.46e-05	CbGpPWpGaD
Mesoridazine—DRD2—Signaling Pathways—PIK3CB—breast cancer	6.48e-06	4.46e-05	CbGpPWpGaD
Mesoridazine—CYP2D6—Metabolism—CAV1—breast cancer	6.48e-06	4.46e-05	CbGpPWpGaD
Mesoridazine—HTR2A—Signaling Pathways—ERBB2—breast cancer	6.46e-06	4.45e-05	CbGpPWpGaD
Mesoridazine—CHRM2—Signaling by GPCR—PIK3CA—breast cancer	6.46e-06	4.45e-05	CbGpPWpGaD
Mesoridazine—HRH1—Signaling Pathways—ERBB2—breast cancer	6.45e-06	4.44e-05	CbGpPWpGaD
Mesoridazine—CHRM2—Signaling Pathways—MDM2—breast cancer	6.43e-06	4.43e-05	CbGpPWpGaD
Mesoridazine—HTR1A—Signaling Pathways—MMP9—breast cancer	6.42e-06	4.42e-05	CbGpPWpGaD
Mesoridazine—CHRM2—Signaling Pathways—RAF1—breast cancer	6.41e-06	4.42e-05	CbGpPWpGaD
Mesoridazine—HTR1A—Signaling Pathways—CDKN1A—breast cancer	6.39e-06	4.4e-05	CbGpPWpGaD
Mesoridazine—CHRM2—Signaling Pathways—RELA—breast cancer	6.38e-06	4.4e-05	CbGpPWpGaD
Mesoridazine—HTR2C—Signaling Pathways—MMP9—breast cancer	6.38e-06	4.4e-05	CbGpPWpGaD
Mesoridazine—HTR1A—Signaling Pathways—PTEN—breast cancer	6.38e-06	4.39e-05	CbGpPWpGaD
Mesoridazine—HTR2A—Signaling Pathways—MTOR—breast cancer	6.38e-06	4.39e-05	CbGpPWpGaD
Mesoridazine—HTR2A—Signaling Pathways—PIK3CB—breast cancer	6.38e-06	4.39e-05	CbGpPWpGaD
Mesoridazine—HRH1—Signaling Pathways—MTOR—breast cancer	6.36e-06	4.38e-05	CbGpPWpGaD
Mesoridazine—HRH1—Signaling Pathways—PIK3CB—breast cancer	6.36e-06	4.38e-05	CbGpPWpGaD
Mesoridazine—HTR2C—Signaling Pathways—CDKN1A—breast cancer	6.36e-06	4.38e-05	CbGpPWpGaD
Mesoridazine—HTR2C—Signaling Pathways—PTEN—breast cancer	6.35e-06	4.37e-05	CbGpPWpGaD
Mesoridazine—CHRM2—Signaling Pathways—ERBB2—breast cancer	6.34e-06	4.37e-05	CbGpPWpGaD
Mesoridazine—CHRM2—Signaling Pathways—PIK3CB—breast cancer	6.26e-06	4.31e-05	CbGpPWpGaD
Mesoridazine—CHRM2—Signaling Pathways—MTOR—breast cancer	6.26e-06	4.31e-05	CbGpPWpGaD
Mesoridazine—DRD3—Signaling Pathways—MAPK3—breast cancer	6.25e-06	4.31e-05	CbGpPWpGaD
Mesoridazine—HTR1A—Signaling Pathways—MAPK8—breast cancer	6.24e-06	4.3e-05	CbGpPWpGaD
Mesoridazine—DRD2—Signaling Pathways—CXCL8—breast cancer	6.23e-06	4.29e-05	CbGpPWpGaD
Mesoridazine—HTR1A—Signaling by GPCR—AKT1—breast cancer	6.22e-06	4.29e-05	CbGpPWpGaD
Mesoridazine—HTR2C—Signaling Pathways—MAPK8—breast cancer	6.21e-06	4.28e-05	CbGpPWpGaD
Mesoridazine—HTR2C—Signaling by GPCR—AKT1—breast cancer	6.19e-06	4.26e-05	CbGpPWpGaD
Mesoridazine—DRD2—Signaling by GPCR—HRAS—breast cancer	6.19e-06	4.26e-05	CbGpPWpGaD
Mesoridazine—HTR2A—Signaling Pathways—CXCL8—breast cancer	6.13e-06	4.22e-05	CbGpPWpGaD
Mesoridazine—HRH1—Signaling Pathways—CXCL8—breast cancer	6.11e-06	4.21e-05	CbGpPWpGaD
Mesoridazine—HTR2A—Signaling by GPCR—HRAS—breast cancer	6.09e-06	4.19e-05	CbGpPWpGaD
Mesoridazine—DRD3—Signaling Pathways—MYC—breast cancer	6.08e-06	4.19e-05	CbGpPWpGaD
Mesoridazine—DRD2—Signaling Pathways—CDKN1B—breast cancer	6.08e-06	4.19e-05	CbGpPWpGaD
Mesoridazine—HTR6—Signaling Pathways—PIK3CA—breast cancer	6.08e-06	4.19e-05	CbGpPWpGaD
Mesoridazine—HRH1—Signaling by GPCR—HRAS—breast cancer	6.07e-06	4.19e-05	CbGpPWpGaD
Mesoridazine—DRD3—Signaling Pathways—TGFB1—breast cancer	6.07e-06	4.18e-05	CbGpPWpGaD
Mesoridazine—CHRM2—Signaling Pathways—CXCL8—breast cancer	6.02e-06	4.15e-05	CbGpPWpGaD
Mesoridazine—DRD2—GPCR downstream signaling—AKT1—breast cancer	6.02e-06	4.14e-05	CbGpPWpGaD
Mesoridazine—HTR2A—Signaling Pathways—CDKN1B—breast cancer	5.98e-06	4.12e-05	CbGpPWpGaD
Mesoridazine—CHRM2—Signaling by GPCR—HRAS—breast cancer	5.98e-06	4.12e-05	CbGpPWpGaD
Mesoridazine—HRH1—Signaling Pathways—CDKN1B—breast cancer	5.97e-06	4.11e-05	CbGpPWpGaD
Mesoridazine—DRD2—Signaling Pathways—CASP3—breast cancer	5.96e-06	4.11e-05	CbGpPWpGaD
Mesoridazine—DRD2—Signaling Pathways—IL2—breast cancer	5.95e-06	4.1e-05	CbGpPWpGaD
Mesoridazine—DRD3—Signaling Pathways—EGFR—breast cancer	5.95e-06	4.1e-05	CbGpPWpGaD
Mesoridazine—DRD2—Signaling by GPCR—IL6—breast cancer	5.92e-06	4.08e-05	CbGpPWpGaD
Mesoridazine—HTR2A—GPCR downstream signaling—AKT1—breast cancer	5.92e-06	4.08e-05	CbGpPWpGaD
Mesoridazine—HTR1A—Signaling Pathways—SRC—breast cancer	5.91e-06	4.08e-05	CbGpPWpGaD
Mesoridazine—HRH1—GPCR downstream signaling—AKT1—breast cancer	5.91e-06	4.07e-05	CbGpPWpGaD
Mesoridazine—CYP2D6—Metabolism—PIK3CG—breast cancer	5.9e-06	4.06e-05	CbGpPWpGaD
Mesoridazine—HTR2C—Signaling Pathways—SRC—breast cancer	5.88e-06	4.05e-05	CbGpPWpGaD
Mesoridazine—HTR6—Signaling Pathways—TP53—breast cancer	5.88e-06	4.05e-05	CbGpPWpGaD
Mesoridazine—CHRM2—Signaling Pathways—CDKN1B—breast cancer	5.88e-06	4.05e-05	CbGpPWpGaD
Mesoridazine—HTR2A—Signaling Pathways—CASP3—breast cancer	5.86e-06	4.04e-05	CbGpPWpGaD
Mesoridazine—HTR2A—Signaling Pathways—IL2—breast cancer	5.86e-06	4.03e-05	CbGpPWpGaD
Mesoridazine—HRH1—Signaling Pathways—CASP3—breast cancer	5.85e-06	4.03e-05	CbGpPWpGaD
Mesoridazine—HRH1—Signaling Pathways—IL2—breast cancer	5.84e-06	4.03e-05	CbGpPWpGaD
Mesoridazine—HTR2A—Signaling by GPCR—IL6—breast cancer	5.83e-06	4.01e-05	CbGpPWpGaD
Mesoridazine—HRH1—Signaling by GPCR—IL6—breast cancer	5.81e-06	4.01e-05	CbGpPWpGaD
Mesoridazine—CHRM2—GPCR downstream signaling—AKT1—breast cancer	5.81e-06	4e-05	CbGpPWpGaD
Mesoridazine—DRD2—Signaling Pathways—CCND1—breast cancer	5.8e-06	4e-05	CbGpPWpGaD
Mesoridazine—DRD2—Signaling Pathways—JUN—breast cancer	5.79e-06	3.99e-05	CbGpPWpGaD
Mesoridazine—HTR1A—Signaling Pathways—VEGFA—breast cancer	5.76e-06	3.97e-05	CbGpPWpGaD
Mesoridazine—CHRM2—Signaling Pathways—CASP3—breast cancer	5.76e-06	3.97e-05	CbGpPWpGaD
Mesoridazine—CHRM2—Signaling Pathways—IL2—breast cancer	5.75e-06	3.96e-05	CbGpPWpGaD
Mesoridazine—DRD2—Signaling Pathways—CTNNB1—breast cancer	5.75e-06	3.96e-05	CbGpPWpGaD
Mesoridazine—HTR2C—Signaling Pathways—VEGFA—breast cancer	5.73e-06	3.95e-05	CbGpPWpGaD
Mesoridazine—CHRM2—Signaling by GPCR—IL6—breast cancer	5.72e-06	3.94e-05	CbGpPWpGaD
Mesoridazine—HTR2A—Signaling Pathways—CCND1—breast cancer	5.71e-06	3.93e-05	CbGpPWpGaD
Mesoridazine—HTR1A—Signaling Pathways—STAT3—breast cancer	5.7e-06	3.93e-05	CbGpPWpGaD
Mesoridazine—HTR2A—Signaling Pathways—JUN—breast cancer	5.7e-06	3.92e-05	CbGpPWpGaD
Mesoridazine—HRH1—Signaling Pathways—CCND1—breast cancer	5.7e-06	3.92e-05	CbGpPWpGaD
Mesoridazine—HRH1—Signaling Pathways—JUN—breast cancer	5.68e-06	3.92e-05	CbGpPWpGaD
Mesoridazine—HTR2C—Signaling Pathways—STAT3—breast cancer	5.67e-06	3.91e-05	CbGpPWpGaD
Mesoridazine—HTR2A—Signaling Pathways—CTNNB1—breast cancer	5.65e-06	3.9e-05	CbGpPWpGaD
Mesoridazine—HRH1—Signaling Pathways—CTNNB1—breast cancer	5.64e-06	3.89e-05	CbGpPWpGaD
Mesoridazine—DRD2—Signaling Pathways—MMP9—breast cancer	5.63e-06	3.88e-05	CbGpPWpGaD
Mesoridazine—HTR6—Signaling Pathways—HRAS—breast cancer	5.62e-06	3.87e-05	CbGpPWpGaD
Mesoridazine—DRD3—Signaling Pathways—KRAS—breast cancer	5.62e-06	3.87e-05	CbGpPWpGaD
Mesoridazine—DRD2—Signaling Pathways—CDKN1A—breast cancer	5.61e-06	3.87e-05	CbGpPWpGaD
Mesoridazine—CHRM2—Signaling Pathways—CCND1—breast cancer	5.61e-06	3.86e-05	CbGpPWpGaD
Mesoridazine—DRD2—Signaling Pathways—PTEN—breast cancer	5.6e-06	3.86e-05	CbGpPWpGaD
Mesoridazine—CHRM2—Signaling Pathways—JUN—breast cancer	5.59e-06	3.85e-05	CbGpPWpGaD
Mesoridazine—CHRM2—Signaling Pathways—CTNNB1—breast cancer	5.55e-06	3.82e-05	CbGpPWpGaD
Mesoridazine—HTR2A—Signaling Pathways—MMP9—breast cancer	5.54e-06	3.82e-05	CbGpPWpGaD
Mesoridazine—HRH1—Signaling Pathways—MMP9—breast cancer	5.53e-06	3.81e-05	CbGpPWpGaD
Mesoridazine—HTR2A—Signaling Pathways—CDKN1A—breast cancer	5.52e-06	3.8e-05	CbGpPWpGaD
Mesoridazine—HRH1—Signaling Pathways—CDKN1A—breast cancer	5.51e-06	3.8e-05	CbGpPWpGaD
Mesoridazine—HTR2A—Signaling Pathways—PTEN—breast cancer	5.51e-06	3.8e-05	CbGpPWpGaD
Mesoridazine—HRH1—Signaling Pathways—PTEN—breast cancer	5.5e-06	3.79e-05	CbGpPWpGaD
Mesoridazine—DRD2—Signaling Pathways—MAPK8—breast cancer	5.48e-06	3.77e-05	CbGpPWpGaD
Mesoridazine—DRD2—Signaling by GPCR—AKT1—breast cancer	5.46e-06	3.76e-05	CbGpPWpGaD
Mesoridazine—HTR1A—Signaling Pathways—MAPK3—breast cancer	5.45e-06	3.75e-05	CbGpPWpGaD
Mesoridazine—CHRM2—Signaling Pathways—MMP9—breast cancer	5.44e-06	3.75e-05	CbGpPWpGaD
Mesoridazine—CHRM2—Signaling Pathways—CDKN1A—breast cancer	5.42e-06	3.74e-05	CbGpPWpGaD
Mesoridazine—HTR2C—Signaling Pathways—MAPK3—breast cancer	5.42e-06	3.74e-05	CbGpPWpGaD
Mesoridazine—CHRM2—Signaling Pathways—PTEN—breast cancer	5.41e-06	3.73e-05	CbGpPWpGaD
Mesoridazine—HTR2A—Signaling Pathways—MAPK8—breast cancer	5.39e-06	3.71e-05	CbGpPWpGaD
Mesoridazine—HTR6—Signaling Pathways—IL6—breast cancer	5.38e-06	3.71e-05	CbGpPWpGaD
Mesoridazine—HRH1—Signaling Pathways—MAPK8—breast cancer	5.38e-06	3.71e-05	CbGpPWpGaD
Mesoridazine—HTR2A—Signaling by GPCR—AKT1—breast cancer	5.38e-06	3.7e-05	CbGpPWpGaD
Mesoridazine—HRH1—Signaling by GPCR—AKT1—breast cancer	5.36e-06	3.7e-05	CbGpPWpGaD
Mesoridazine—HTR1A—Signaling Pathways—MYC—breast cancer	5.3e-06	3.65e-05	CbGpPWpGaD
Mesoridazine—CHRM2—Signaling Pathways—MAPK8—breast cancer	5.29e-06	3.65e-05	CbGpPWpGaD
Mesoridazine—HTR1A—Signaling Pathways—TGFB1—breast cancer	5.29e-06	3.64e-05	CbGpPWpGaD
Mesoridazine—CHRM2—Signaling by GPCR—AKT1—breast cancer	5.28e-06	3.64e-05	CbGpPWpGaD
Mesoridazine—HTR2C—Signaling Pathways—MYC—breast cancer	5.27e-06	3.63e-05	CbGpPWpGaD
Mesoridazine—HTR2C—Signaling Pathways—TGFB1—breast cancer	5.26e-06	3.62e-05	CbGpPWpGaD
Mesoridazine—DRD2—Signaling Pathways—SRC—breast cancer	5.19e-06	3.58e-05	CbGpPWpGaD
Mesoridazine—CYP2D6—Metabolism—PIK3CD—breast cancer	5.19e-06	3.57e-05	CbGpPWpGaD
Mesoridazine—HTR1A—Signaling Pathways—EGFR—breast cancer	5.18e-06	3.57e-05	CbGpPWpGaD
Mesoridazine—DRD3—Signaling Pathways—PIK3CA—breast cancer	5.16e-06	3.56e-05	CbGpPWpGaD
Mesoridazine—HTR2C—Signaling Pathways—EGFR—breast cancer	5.16e-06	3.55e-05	CbGpPWpGaD
Mesoridazine—CYP2D6—Metabolism—ALB—breast cancer	5.12e-06	3.53e-05	CbGpPWpGaD
Mesoridazine—HTR2A—Signaling Pathways—SRC—breast cancer	5.11e-06	3.52e-05	CbGpPWpGaD
Mesoridazine—HRH1—Signaling Pathways—SRC—breast cancer	5.1e-06	3.51e-05	CbGpPWpGaD
Mesoridazine—DRD2—Signaling Pathways—VEGFA—breast cancer	5.06e-06	3.48e-05	CbGpPWpGaD
Mesoridazine—CHRM2—Signaling Pathways—SRC—breast cancer	5.02e-06	3.46e-05	CbGpPWpGaD
Mesoridazine—DRD2—Signaling Pathways—STAT3—breast cancer	5.01e-06	3.45e-05	CbGpPWpGaD
Mesoridazine—DRD3—Signaling Pathways—TP53—breast cancer	4.99e-06	3.44e-05	CbGpPWpGaD
Mesoridazine—HTR2A—Signaling Pathways—VEGFA—breast cancer	4.98e-06	3.43e-05	CbGpPWpGaD
Mesoridazine—HRH1—Signaling Pathways—VEGFA—breast cancer	4.97e-06	3.42e-05	CbGpPWpGaD
Mesoridazine—HTR6—Signaling Pathways—AKT1—breast cancer	4.97e-06	3.42e-05	CbGpPWpGaD
Mesoridazine—HTR2A—Signaling Pathways—STAT3—breast cancer	4.93e-06	3.4e-05	CbGpPWpGaD
Mesoridazine—HRH1—Signaling Pathways—STAT3—breast cancer	4.92e-06	3.39e-05	CbGpPWpGaD
Mesoridazine—CYP2D6—Metabolism—NOS3—breast cancer	4.9e-06	3.37e-05	CbGpPWpGaD
Mesoridazine—HTR1A—Signaling Pathways—KRAS—breast cancer	4.9e-06	3.37e-05	CbGpPWpGaD
Mesoridazine—CHRM2—Signaling Pathways—VEGFA—breast cancer	4.89e-06	3.37e-05	CbGpPWpGaD
Mesoridazine—HTR2C—Signaling Pathways—KRAS—breast cancer	4.87e-06	3.36e-05	CbGpPWpGaD
Mesoridazine—CHRM2—Signaling Pathways—STAT3—breast cancer	4.84e-06	3.33e-05	CbGpPWpGaD
Mesoridazine—DRD2—Signaling Pathways—MAPK3—breast cancer	4.78e-06	3.3e-05	CbGpPWpGaD
Mesoridazine—DRD3—Signaling Pathways—HRAS—breast cancer	4.78e-06	3.29e-05	CbGpPWpGaD
Mesoridazine—HTR2A—Signaling Pathways—MAPK3—breast cancer	4.71e-06	3.24e-05	CbGpPWpGaD
Mesoridazine—HRH1—Signaling Pathways—MAPK3—breast cancer	4.7e-06	3.24e-05	CbGpPWpGaD
Mesoridazine—DRD2—Signaling Pathways—MYC—breast cancer	4.65e-06	3.21e-05	CbGpPWpGaD
Mesoridazine—DRD2—Signaling Pathways—TGFB1—breast cancer	4.64e-06	3.2e-05	CbGpPWpGaD
Mesoridazine—CHRM2—Signaling Pathways—MAPK3—breast cancer	4.62e-06	3.18e-05	CbGpPWpGaD
Mesoridazine—HTR2A—Signaling Pathways—MYC—breast cancer	4.58e-06	3.15e-05	CbGpPWpGaD
Mesoridazine—DRD3—Signaling Pathways—IL6—breast cancer	4.57e-06	3.15e-05	CbGpPWpGaD
Mesoridazine—HRH1—Signaling Pathways—MYC—breast cancer	4.57e-06	3.15e-05	CbGpPWpGaD
Mesoridazine—HTR2A—Signaling Pathways—TGFB1—breast cancer	4.57e-06	3.15e-05	CbGpPWpGaD
Mesoridazine—HRH1—Signaling Pathways—TGFB1—breast cancer	4.56e-06	3.14e-05	CbGpPWpGaD
Mesoridazine—DRD2—Signaling Pathways—EGFR—breast cancer	4.55e-06	3.14e-05	CbGpPWpGaD
Mesoridazine—CYP2D6—Metabolism—PIK3CB—breast cancer	4.52e-06	3.11e-05	CbGpPWpGaD
Mesoridazine—HTR1A—Signaling Pathways—PIK3CA—breast cancer	4.5e-06	3.1e-05	CbGpPWpGaD
Mesoridazine—CHRM2—Signaling Pathways—MYC—breast cancer	4.5e-06	3.1e-05	CbGpPWpGaD
Mesoridazine—CHRM2—Signaling Pathways—TGFB1—breast cancer	4.49e-06	3.09e-05	CbGpPWpGaD
Mesoridazine—CYP2D6—Metabolism—PTGS2—breast cancer	4.48e-06	3.09e-05	CbGpPWpGaD
Mesoridazine—HTR2A—Signaling Pathways—EGFR—breast cancer	4.48e-06	3.09e-05	CbGpPWpGaD
Mesoridazine—HTR2C—Signaling Pathways—PIK3CA—breast cancer	4.48e-06	3.08e-05	CbGpPWpGaD
Mesoridazine—HRH1—Signaling Pathways—EGFR—breast cancer	4.47e-06	3.08e-05	CbGpPWpGaD
Mesoridazine—CHRM2—Signaling Pathways—EGFR—breast cancer	4.4e-06	3.03e-05	CbGpPWpGaD
Mesoridazine—HTR1A—Signaling Pathways—TP53—breast cancer	4.35e-06	3e-05	CbGpPWpGaD
Mesoridazine—HTR2C—Signaling Pathways—TP53—breast cancer	4.33e-06	2.98e-05	CbGpPWpGaD
Mesoridazine—DRD2—Signaling Pathways—KRAS—breast cancer	4.3e-06	2.96e-05	CbGpPWpGaD
Mesoridazine—HTR2A—Signaling Pathways—KRAS—breast cancer	4.23e-06	2.92e-05	CbGpPWpGaD
Mesoridazine—HRH1—Signaling Pathways—KRAS—breast cancer	4.22e-06	2.91e-05	CbGpPWpGaD
Mesoridazine—DRD3—Signaling Pathways—AKT1—breast cancer	4.22e-06	2.91e-05	CbGpPWpGaD
Mesoridazine—HTR1A—Signaling Pathways—HRAS—breast cancer	4.16e-06	2.87e-05	CbGpPWpGaD
Mesoridazine—CHRM2—Signaling Pathways—KRAS—breast cancer	4.15e-06	2.86e-05	CbGpPWpGaD
Mesoridazine—HTR2C—Signaling Pathways—HRAS—breast cancer	4.14e-06	2.85e-05	CbGpPWpGaD
Mesoridazine—HTR1A—Signaling Pathways—IL6—breast cancer	3.98e-06	2.75e-05	CbGpPWpGaD
Mesoridazine—HTR2C—Signaling Pathways—IL6—breast cancer	3.96e-06	2.73e-05	CbGpPWpGaD
Mesoridazine—DRD2—Signaling Pathways—PIK3CA—breast cancer	3.95e-06	2.72e-05	CbGpPWpGaD
Mesoridazine—CYP2D6—Metabolism—PTEN—breast cancer	3.91e-06	2.69e-05	CbGpPWpGaD
Mesoridazine—HTR2A—Signaling Pathways—PIK3CA—breast cancer	3.89e-06	2.68e-05	CbGpPWpGaD
Mesoridazine—HRH1—Signaling Pathways—PIK3CA—breast cancer	3.88e-06	2.67e-05	CbGpPWpGaD
Mesoridazine—DRD2—Signaling Pathways—TP53—breast cancer	3.82e-06	2.63e-05	CbGpPWpGaD
Mesoridazine—CHRM2—Signaling Pathways—PIK3CA—breast cancer	3.82e-06	2.63e-05	CbGpPWpGaD
Mesoridazine—HTR2A—Signaling Pathways—TP53—breast cancer	3.76e-06	2.59e-05	CbGpPWpGaD
Mesoridazine—HRH1—Signaling Pathways—TP53—breast cancer	3.75e-06	2.59e-05	CbGpPWpGaD
Mesoridazine—CHRM2—Signaling Pathways—TP53—breast cancer	3.69e-06	2.54e-05	CbGpPWpGaD
Mesoridazine—HTR1A—Signaling Pathways—AKT1—breast cancer	3.68e-06	2.53e-05	CbGpPWpGaD
Mesoridazine—HTR2C—Signaling Pathways—AKT1—breast cancer	3.66e-06	2.52e-05	CbGpPWpGaD
Mesoridazine—DRD2—Signaling Pathways—HRAS—breast cancer	3.66e-06	2.52e-05	CbGpPWpGaD
Mesoridazine—HTR2A—Signaling Pathways—HRAS—breast cancer	3.6e-06	2.48e-05	CbGpPWpGaD
Mesoridazine—HRH1—Signaling Pathways—HRAS—breast cancer	3.59e-06	2.47e-05	CbGpPWpGaD
Mesoridazine—CHRM2—Signaling Pathways—HRAS—breast cancer	3.53e-06	2.43e-05	CbGpPWpGaD
Mesoridazine—DRD2—Signaling Pathways—IL6—breast cancer	3.5e-06	2.41e-05	CbGpPWpGaD
Mesoridazine—HTR2A—Signaling Pathways—IL6—breast cancer	3.44e-06	2.37e-05	CbGpPWpGaD
Mesoridazine—HRH1—Signaling Pathways—IL6—breast cancer	3.43e-06	2.37e-05	CbGpPWpGaD
Mesoridazine—CHRM2—Signaling Pathways—IL6—breast cancer	3.38e-06	2.33e-05	CbGpPWpGaD
Mesoridazine—DRD2—Signaling Pathways—AKT1—breast cancer	3.23e-06	2.22e-05	CbGpPWpGaD
Mesoridazine—HTR2A—Signaling Pathways—AKT1—breast cancer	3.18e-06	2.19e-05	CbGpPWpGaD
Mesoridazine—HRH1—Signaling Pathways—AKT1—breast cancer	3.17e-06	2.18e-05	CbGpPWpGaD
Mesoridazine—CHRM2—Signaling Pathways—AKT1—breast cancer	3.12e-06	2.15e-05	CbGpPWpGaD
Mesoridazine—CYP2D6—Metabolism—PIK3CA—breast cancer	2.76e-06	1.9e-05	CbGpPWpGaD
Mesoridazine—CYP2D6—Metabolism—AKT1—breast cancer	2.25e-06	1.55e-05	CbGpPWpGaD
